Related Experiment Video
Updated: Mar 20, 2026
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
DNA vaccines to attack cancer: Strategies for improving immunogenicity and efficacy
Angeliki Tiptiri-Kourpeti1, Katerina Spyridopoulou1, Aglaia Pappa1
1Department of Molecular Biology and Genetics, Democritus University of Thrace, University Campus-Dragana, 68100 Alexandroupolis, Greece.
Abstract:
DNA vaccination represents a smart and promising approach to cancer immunotherapy. DNA vaccines for cancer immunotherapy are designed to deliver one or several genes encoding tumor antigens, thereby eliciting or augmenting antigen-specific immune responses against antigens that play a central role in tumor initiation, progression and metastasis. Vaccine efficacy can be significantly improved by implementing strategies for enhancing antigen presentation and immunogenicity, such as new delivery systems, addition of molecular adjuvants and immunostimulatory signals, optimized prime-boost strategies or blockade of immune checkpoints. Taken into consideration that innate immune responses are important in the induction and enhancement of antigen-specific adaptive responses, manipulations that integrate these approaches in the vaccine design can achieve activation of protective adaptive immune responses, thereby overcoming the self-tolerance towards many tumor antigens. Such approaches are employed in a number of clinical trials for DNA cancer immunotherapy and hold promise for prophylactic and therapeutic vaccine development. In this context, strategies that improve immunogenicity and enhance the efficacy of DNA vaccines for cancer immunotherapy are discussed.
Insights
DNA vaccines offer a promising strategy for cancer immunotherapy by delivering tumor antigen genes to stimulate immune responses. Enhancing vaccine efficacy involves optimizing delivery, adjuvants, and immune checkpoint blockade for better cancer treatment.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- DNA vaccination is a key strategy in cancer immunotherapy.
- DNA vaccines deliver genes encoding tumor antigens to elicit immune responses against cancer.
- Tumor antigens are crucial in cancer initiation, progression, and metastasis.
Purpose of the Study:
- To discuss strategies for improving DNA vaccine efficacy in cancer immunotherapy.
- To explore methods for enhancing antigen presentation and immunogenicity.
- To highlight the role of innate immune responses in vaccine design.
Main Methods:
- Reviewing strategies like novel delivery systems, molecular adjuvants, and immunostimulatory signals.
- Examining optimized prime-boost regimens and immune checkpoint blockade.
- Integrating innate immune activation into DNA vaccine design.
Main Results:
- Enhanced antigen presentation and immunogenicity significantly improve vaccine efficacy.
- Combining strategies can overcome self-tolerance towards tumor antigens.
- Clinical trials are evaluating these advanced DNA cancer immunotherapy approaches.
Conclusions:
- DNA vaccines hold significant promise for both prophylactic and therapeutic cancer vaccines.
- Optimizing vaccine design by incorporating innate immune responses is crucial.
- Further research and clinical trials are essential for advancing DNA cancer immunotherapy.
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:21Vaccines